Publicité
Publicité

PALI

PALI logo

Palisade Bio, Inc. Common Stock

1.96
USD
Sponsorisé
+0.06
+2.89%
09 janv., 13:36 UTC -5
Ouvert

PALI Rapports sur les bénéfices

Ratio de surprise positive

PALI a dépassé 15 des 24 dernières estimations.

63%

Prochain rapport

Date du prochain rapport
23 mars 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.14
Variation implicite de Q3 25 (Revenue/ EPS)
--
/
-63.16%
Variation implicite de Q4 24 (Revenue/ EPS)
--
/
-90.91%

Palisade Bio, Inc. Common Stock earnings per share and revenue

On 10 nov. 2025, PALI reported earnings of -0.38 USD per share (EPS) for Q3 25, missing the estimate of -0.27 USD, resulting in a -35.81% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +2.82% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analystes forecast an EPS of -0.14 USD, with revenue projected to reach -- USD, implying an baisse of -63.16% EPS, and hausse of 0.00% in Revenue from the last quarter.
FAQ
For Q3 2025, Palisade Bio, Inc. Common Stock reported EPS of -$0.38, missing estimates by -35.81%, and revenue of $0.00, 0% as expectations.
The stock price moved up 2.82%, changed from $1.77 before the earnings release to $1.82 the day after.
The next earning report is scheduled for 23 mars 2026.
Based on 5 analystes, Palisade Bio, Inc. Common Stock is expected to report EPS of -$0.14 and revenue of -- for Q4 2025.
Chèque FXEmpire's Earnings Calendar for today's list of reporting companies.
Publicité